NZ755747A - Ampa receptor potentiators - Google Patents
Ampa receptor potentiatorsInfo
- Publication number
- NZ755747A NZ755747A NZ755747A NZ75574718A NZ755747A NZ 755747 A NZ755747 A NZ 755747A NZ 755747 A NZ755747 A NZ 755747A NZ 75574718 A NZ75574718 A NZ 75574718A NZ 755747 A NZ755747 A NZ 755747A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compounds
- disorders
- ampa receptor
- treatment
- receptor potentiators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1702221.1A GB201702221D0 (en) | 2017-02-10 | 2017-02-10 | Compounds |
| PCT/GB2018/050370 WO2018146486A1 (en) | 2017-02-10 | 2018-02-09 | Ampa receptor potentiators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ755747A true NZ755747A (en) | 2022-02-25 |
Family
ID=58462168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ755747A NZ755747A (en) | 2017-02-10 | 2018-02-09 | Ampa receptor potentiators |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11186567B2 (OSRAM) |
| EP (1) | EP3580213B1 (OSRAM) |
| JP (1) | JP7014808B2 (OSRAM) |
| KR (1) | KR102665887B1 (OSRAM) |
| CN (1) | CN110520418B (OSRAM) |
| AU (1) | AU2018218307C1 (OSRAM) |
| ES (1) | ES2974824T3 (OSRAM) |
| GB (1) | GB201702221D0 (OSRAM) |
| MX (1) | MX2019009537A (OSRAM) |
| NZ (1) | NZ755747A (OSRAM) |
| RU (1) | RU2019126574A (OSRAM) |
| WO (1) | WO2018146486A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
| WO2024255822A1 (zh) * | 2023-06-15 | 2024-12-19 | 上海魁特迪生物科技有限公司 | Dir结合剂及其用途 |
| CN121652294A (zh) * | 2026-02-06 | 2026-03-13 | 首都医科大学宣武医院 | 一种用于检测抗ampar1抗体的融合蛋白及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW575561B (en) | 1999-03-25 | 2004-02-11 | Hoffmann La Roche | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives |
| ES2320973T3 (es) | 2000-06-12 | 2009-06-01 | EISAI R&D MANAGEMENT CO., LTD. | Compuestos de 1,2-dihidropiridina, procedimiento para su preparacion y uso de los mismos. |
| AU2003302027A1 (en) | 2002-11-21 | 2004-06-15 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| WO2006109056A1 (en) | 2005-04-12 | 2006-10-19 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| CA2646585A1 (en) | 2006-03-20 | 2007-09-27 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses thereof in medicine |
| EA016415B1 (ru) | 2006-04-24 | 2012-04-30 | Эли Лилли Энд Компани | Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1 |
| TW200817385A (en) * | 2006-07-04 | 2008-04-16 | Organon Nv | Heterocyclic derivatives |
| DE602007013450D1 (de) * | 2006-11-03 | 2011-05-05 | Glaxo Group Ltd | Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin |
| GB0711089D0 (en) | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| GB0711088D0 (en) | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| JP5470557B2 (ja) | 2007-07-26 | 2014-04-16 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の合成 |
| EP2195303A4 (en) | 2007-09-20 | 2011-07-20 | Cortex Pharma Inc | 3-SUBSTITUTED 1,2,3-TRIAZIN-4-ONE AND 3-SUBSTITUTED 1,3-PYRIMIDIONE FOR INCREASING GLUTAMATERGIC SYNAPTIC REACTIONS |
| GB0721094D0 (en) | 2007-10-26 | 2007-12-05 | Glaxo Group Ltd | Compounds |
| TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
| JP5696037B2 (ja) | 2008-05-01 | 2015-04-08 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター |
| TW201012803A (en) * | 2008-06-06 | 2010-04-01 | Organon Nv | Heterocyclic derivatives |
| TW201031649A (en) | 2008-12-02 | 2010-09-01 | Organon Nv | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives |
| BRPI1014583B1 (pt) | 2009-06-26 | 2020-03-31 | Pfizer, Inc. | Sulfonamidas heterocíclicas e composições farmacêuticas |
| WO2011132051A2 (en) | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Tricycle compounds as phosphodiesterase-10 inhibitors |
| UY33930A (es) | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
-
2017
- 2017-02-10 GB GBGB1702221.1A patent/GB201702221D0/en not_active Ceased
-
2018
- 2018-02-09 US US16/482,791 patent/US11186567B2/en active Active
- 2018-02-09 KR KR1020197024520A patent/KR102665887B1/ko active Active
- 2018-02-09 MX MX2019009537A patent/MX2019009537A/es unknown
- 2018-02-09 RU RU2019126574A patent/RU2019126574A/ru unknown
- 2018-02-09 WO PCT/GB2018/050370 patent/WO2018146486A1/en not_active Ceased
- 2018-02-09 NZ NZ755747A patent/NZ755747A/en unknown
- 2018-02-09 CN CN201880023973.3A patent/CN110520418B/zh active Active
- 2018-02-09 JP JP2019543832A patent/JP7014808B2/ja active Active
- 2018-02-09 AU AU2018218307A patent/AU2018218307C1/en active Active
- 2018-02-09 ES ES18705480T patent/ES2974824T3/es active Active
- 2018-02-09 EP EP18705480.4A patent/EP3580213B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018218307C1 (en) | 2022-06-23 |
| ES2974824T3 (es) | 2024-07-01 |
| CN110520418B (zh) | 2022-08-16 |
| JP7014808B2 (ja) | 2022-02-01 |
| JP2020507592A (ja) | 2020-03-12 |
| US11186567B2 (en) | 2021-11-30 |
| MX2019009537A (es) | 2019-10-04 |
| WO2018146486A1 (en) | 2018-08-16 |
| AU2018218307B2 (en) | 2022-02-24 |
| CA3051647A1 (en) | 2018-08-16 |
| EP3580213B1 (en) | 2024-03-27 |
| RU2019126574A (ru) | 2021-03-10 |
| CN110520418A (zh) | 2019-11-29 |
| BR112019016603A2 (pt) | 2020-03-31 |
| KR20190117549A (ko) | 2019-10-16 |
| AU2018218307A1 (en) | 2019-08-15 |
| EP3580213A1 (en) | 2019-12-18 |
| KR102665887B1 (ko) | 2024-05-10 |
| EP3580213C0 (en) | 2024-03-27 |
| US20210139463A1 (en) | 2021-05-13 |
| RU2019126574A3 (OSRAM) | 2021-03-29 |
| GB201702221D0 (en) | 2017-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501570B1 (en) | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists | |
| PH12016501791A1 (en) | Muscarinic receptor agonists | |
| GEAP202014908A (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| JO3316B1 (ar) | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل | |
| MX366623B (es) | 5-(3,5-dimetilisoxazol-4-il)indolina-2-onas sustituidas. | |
| GEAP202014955A (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| PH12016501624A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| GEP20196961B (en) | 4-oxo-3,4-dihydro-1,2,3 -benzotriazines modulators of gpr139 | |
| GEAP202115340A (en) | Pyrimidine compound as jak kinase inhibitor | |
| NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
| CL2018001085A1 (es) | Derivados de indolin-2-ona | |
| SG10201805267UA (en) | Piperazine derivatives having multimodal activity against pain | |
| MY201535A (en) | Therapeutic compounds | |
| NZ755747A (en) | Ampa receptor potentiators | |
| PH12016501393A1 (en) | Substituted bicyclic heteroaryl compounds as rxr agonists | |
| MX2014000963A (es) | Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide. | |
| MX2018014185A (es) | Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa. | |
| MX2020009097A (es) | Compuestos que modulan la funcion del receptor de ampa. | |
| MX2018004256A (es) | Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos. | |
| GB2519470A (en) | Bicyclic aza compounds as muscarinic M1 receptor agonists | |
| PH12017501209A1 (en) | Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors | |
| PH12019550251A1 (en) | HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | |
| MX375551B (es) | Nuevas imidazo[1,2-a]quinoxalinas y derivados de las mismas para el tratamiento contra cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 FEB 2024 BY IP CENTRUM LIMITED Effective date: 20230127 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 FEB 2025 BY IP CENTRUM LIMITED Effective date: 20240113 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 FEB 2026 BY CPA GLOBAL (PATRAFEE) AB Effective date: 20250130 |
|
| ASS | Change of ownership |
Owner name: DRAIG THERAPEUTICS LTD, GB Effective date: 20250902 |